Hemcheck has performed a directed share issue of ca 15 MSEK

The board of Hemcheck Sweden AB (publ) (“Hemcheck” or “The Company”) has, through the authorization given by the extra general meeting held on December 15th 2020, and according to what The Company indicated in a press release on January 18th 2021, performed a directed share issue of 3 580 000 shares at a price of 4.20 SEK per share (the “Directed Issue”). The share price has been set according to an accelerated bookbuilding-process carried out by Corpura Fondkommission AB. The Directed Issue will provide The Company ca 15 MSEK before transaction costs.

The investors in the Directed Issue are a number of new and current professional Swedish investors.

The Directed Issue is done to strengthen The Company’s financial position and create conditions for The Company to:

  • Continue focusing on securing additional reference and end customers, studies, as well as collaborations with external parties such as distributors and other potential partners,
  • Finalize the development/CE-marking process and launch of The Company’s new product for the blood gas market including related patent processes,
  • Invest in a more efficient production process related to the one-time disposable tests

-We will be stronger with this additional capital and it will allow us to increase our commercialization efforts, but also continue our work in other areas such as taking the new product for the blood gas market through the CE-marking process. We look forward to an exciting 2021, says Joen Averstad, CEO of Hemcheck.

The reasons for deviating from the shareholders’ preferential rights is to expand the shareholder base and at the same time acquire capital in an efficient way. The price per share is equivalent to a discount of 6.2 percent compared to the volume-weighted average share price for Hemcheck’s share during the 20 days prior to the Directed Issue. The board has assessed that the share price in the Directed Issue is market based, since the share price in the Directed Issue has been determined through an accelerated bookbuilding-process.

The Directed Issue will increase the number of shares and votes in The Company by 3 580 000, from 15 708 230 shares and votes to 19 288 230 shares and votes, and the share capital increases with 322 200 SEK, from 1 413 740.70 SEK to 1 735 940.70 SEK, equivalent to a dilution of 18.6 percent of the number of shares and votes in The Company, after the Directed Issue.


Corpura Fondkommission AB is the financial advisor and Fredersen Advokatbyrå AB is the legal advisor to Hemcheck in connection to the directed share issue. Aqurat Fondkommission AB is the issuer agent.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on January 19, 2021 at 08:20.

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

Important information


The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Hemcheck in any jurisdiction.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied or distributed, directly or indirectly, in whole or in part, within or into the United States of America, Canada, Japan, South Africa, Australia or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Hemcheck has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Share Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this press release relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward looking statements

This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.